HC Wainwright Analysts Boost Earnings Estimates for uniQure

uniQure N.V. (NASDAQ:QURE) – Analysts at HC Wainwright boosted their Q1 2026 earnings per share estimates for uniQure in a research note issued to investors on Tuesday, November 4th. HC Wainwright analyst P. Trucchio now forecasts that the biotechnology company will post earnings per share of ($0.53) for the quarter, up from their prior estimate of ($0.59). HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. HC Wainwright also issued estimates for uniQure’s Q2 2026 earnings at ($0.55) EPS, Q3 2026 earnings at ($0.57) EPS, Q4 2026 earnings at ($0.64) EPS, FY2026 earnings at ($2.29) EPS, FY2027 earnings at ($2.68) EPS, FY2028 earnings at ($1.51) EPS and FY2029 earnings at $3.90 EPS.

Several other research analysts have also recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, October 8th. Stifel Nicolaus increased their target price on uniQure from $30.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. The Goldman Sachs Group decreased their target price on uniQure from $56.00 to $38.00 and set a “neutral” rating on the stock in a research report on Tuesday. Royal Bank Of Canada reduced their price objective on uniQure from $65.00 to $45.00 and set an “outperform” rating on the stock in a research report on Monday. Finally, William Blair downgraded uniQure from an “outperform” rating to a “market perform” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $66.75.

uniQure Trading Down 14.4%

uniQure stock opened at $26.06 on Thursday. uniQure has a one year low of $5.50 and a one year high of $71.50. The stock has a market cap of $1.43 billion, a PE ratio of -6.65 and a beta of 0.59. The company has a debt-to-equity ratio of 1.53, a quick ratio of 9.98 and a current ratio of 9.98. The stock has a 50-day moving average of $41.62 and a two-hundred day moving average of $24.04.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of QURE. Private Trust Co. NA purchased a new position in uniQure in the third quarter valued at about $28,000. Jones Financial Companies Lllp lifted its position in shares of uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares during the last quarter. Ballentine Partners LLC purchased a new stake in shares of uniQure in the third quarter valued at $301,000. Tower Research Capital LLC TRC lifted its holdings in shares of uniQure by 358.0% in the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 5,538 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new position in shares of uniQure in the third quarter worth $454,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 226,316 shares of the company’s stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total value of $9,383,061.36. Following the completion of the sale, the chief executive officer directly owned 651,454 shares of the company’s stock, valued at $27,009,282.84. This represents a 25.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Christian Klemt sold 15,000 shares of the stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $55.00, for a total value of $825,000.00. Following the sale, the chief financial officer directly owned 217,730 shares of the company’s stock, valued at $11,975,150. The trade was a 6.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 244,316 shares of company stock valued at $10,328,181. Insiders own 4.79% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.